Retinal Vein Occlusion Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 138 Published: November 30, 2021 Report Code: GMDGDHC13153IDB

Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of retinal vein occlusion is a sudden painless change in vision. Predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol, and age.

The retinal vein occlusion drugs in development market research report provides comprehensive information on the therapeutics under development for retinal vein occlusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for retinal vein occlusion and features dormant and discontinued projects.

What are the key targets in the retinal vein occlusion pipeline products market?

The key targets in the retinal vein occlusion pipeline products market are vascular endothelial growth factor, vascular endothelial growth factor A, glucocorticoid receptor, phospholipase A2, placenta growth factor, protein kinase C, vascular endothelial growth factor receptor 2, angiopoietin 1 receptor, angiopoietin 2, calpain 1 catalytic subunit, and others.

Retinal Vein Occlusion Pipeline Products Analysis Market by Targets

Retinal Vein Occlusion Pipeline Products Analysis Market by Targets

For more target insights, download a free report sample

What are the key mechanisms of action in the retinal vein occlusion pipeline products market?

The key mechanisms of action in the retinal vein occlusion pipeline products market are vascular endothelial growth factor inhibitor, vascular endothelial growth factor A inhibitor, phospholipase A2 inhibitor, placenta growth factor inhibitor, protein kinase C inhibitor, glucocorticoid receptor agonist, vascular endothelial growth factor receptor 2 inhibitor, angiopoietin 1 receptor agonist, angiopoietin 2 inhibitor, calpain 1 catalytic subunit inhibitor, and others.

Retinal Vein Occlusion Pipeline Products Market Analysis by Mechanism of Actions

Retinal Vein Occlusion Pipeline Products Market Analysis by Mechanism of Actions

For more mechanism of action insights, download a free report sample

What are the key routes of administration in the retinal vein occlusion pipeline products market?

The key routes of administration in the retinal vein occlusion pipeline products market are intravitreal, intravenous, intraocular, ophthalmic, and topical.

Retinal Vein Occlusion Pipeline Products Market Analysis by Routes of Administration

Retinal Vein Occlusion Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

What are the different molecule types in the retinal vein occlusion pipeline products market?

The different molecule types in the retinal vein occlusion pipeline products market are small molecule, monoclonal antibody, synthetic peptide, fusion protein, recombinant protein, gene therapy, aptamer, monoclonal antibody conjugated, and protein.

Retinal Vein Occlusion Pipeline Products Market Analysis by Molecule Type

Retinal Vein Occlusion Pipeline Products Market Analysis by Molecule Type

For more molecule type insights, download a free report sample

Which are the major companies in the retinal vein occlusion pipeline products market?

The major companies in the retinal vein occlusion pipeline products market are ANBITION Srl, Ocular Therapeutix Inc, Annexin Pharmaceuticals AB, Avirmax Inc, Kala Pharmaceuticals Inc, Ripple therapeutics Corp, 3SBio Inc, Allgenesis Biotherapeutics Inc, AsclepiX Therapeutics Inc, and Calpain Therapeutics Pty Ltd.

Retinal Vein Occlusion Pipeline Products Market Analysis by Companies

Retinal Vein Occlusion Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Market Report Scope

Key targets Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Glucocorticoid Receptor, Phospholipase A2, Placenta Growth Factor, Protein Kinase C, Vascular Endothelial Growth Factor Receptor 2, Angiopoietin 1 Receptor, Angiopoietin 2, Calpain 1 Catalytic Subunit, and Others
Key mechanism of action Vascular Endothelial Growth Factor Inhibitor, Vascular Endothelial Growth Factor A Inhibitor, Phospholipase A2 Inhibitor, Placenta Growth Factor Inhibitor, Protein Kinase C Inhibitor, Glucocorticoid Receptor Agonist, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Angiopoietin 1 Receptor Agonist, Angiopoietin 2 Inhibitor, Calpain 1 Catalytic Subunit Inhibitor, and Others
Key routes of administration Intravitreal, Intravenous, Intraocular, Ophthalmic, And Topical
Molecule type Small Molecule, Monoclonal Antibody, Synthetic Peptide, Fusion Protein, Recombinant Protein, Gene Therapy, Aptamer, Monoclonal Antibody Conjugated, And Protein
Major companies ANBITION Srl, Ocular Therapeutix Inc, Annexin Pharmaceuticals AB, Avirmax Inc, Kala Pharmaceuticals Inc, Ripple therapeutics Corp, 3SBio Inc, Allgenesis Biotherapeutics Inc, AsclepiX Therapeutics Inc, and Calpain Therapeutics Pty Ltd

Scope

  • The report provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion
  • The report reviews pipeline therapeutics for Retinal Vein Occlusion by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Retinal Vein Occlusion therapeutics and enlists all their major and minor projects
  • The report assesses Retinal Vein Occlusion therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews the latest news related to pipeline therapeutics for Retinal Vein Occlusion

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Retinal Vein Occlusion
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Retinal Vein Occlusion pipeline depth and focus on Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from the pipeline

Key Players

  • 3SBio Inc

    Allgenesis Biotherapeutics Inc

    ANBITION Srl

    Annexin Pharmaceuticals AB

    AsclepiX Therapeutics Inc

    Avirmax Inc

    Calpain Therapeutics Pty Ltd

    Chengdu Kanghong Pharmaceuticals Group Co Ltd

    Drive Therapeutics LLC

    EyePoint Pharmaceuticals Inc

    F. Hoffmann-La Roche Ltd

    Graybug Vision Inc

    Kala Pharmaceuticals Inc

    Kiora Pharmaceuticals Inc

    Kodiak Sciences Inc

    Luye Pharma Group Ltd

    Novartis AG

    Novelty Nobility Inc

    Ocular Therapeutix Inc

    Outlook Therapeutics Inc

    Oxular Ltd

    Oxurion NV

    Ripple therapeutics Corp

    Samsung Bioepis Co Ltd

    SIFI SpA

    Uni-Bio Science Group Ltd

Table of Contents

Table of Contents

Introduction

Global Markets Direct Report Coverage

Retinal Vein Occlusion – Overview

Retinal Vein Occlusion – Therapeutics Development

Retinal Vein Occlusion – Therapeutics Assessment

Retinal Vein Occlusion – Companies Involved in Therapeutics Development

Retinal Vein Occlusion – Drug Profiles

Retinal Vein Occlusion – Dormant Projects

Retinal Vein Occlusion – Discontinued Products

Retinal Vein Occlusion – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Retinal Vein Occlusion, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Retinal Vein Occlusion – Pipeline by 3SBio Inc, 2021

Retinal Vein Occlusion – Pipeline by Allgenesis Biotherapeutics Inc, 2021

Retinal Vein Occlusion – Pipeline by ANBITION Srl, 2021

Retinal Vein Occlusion – Pipeline by Annexin Pharmaceuticals AB, 2021

Retinal Vein Occlusion – Pipeline by AsclepiX Therapeutics Inc, 2021

Retinal Vein Occlusion – Pipeline by Avirmax Inc, 2021

Retinal Vein Occlusion – Pipeline by Calpain Therapeutics Pty Ltd, 2021

Retinal Vein Occlusion – Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, 2021

Retinal Vein Occlusion – Pipeline by Drive Therapeutics LLC, 2021

Retinal Vein Occlusion – Pipeline by EyePoint Pharmaceuticals Inc, 2021

Retinal Vein Occlusion – Pipeline by F. Hoffmann-La Roche Ltd, 2021

Retinal Vein Occlusion – Pipeline by Graybug Vision Inc, 2021

Retinal Vein Occlusion – Pipeline by Kala Pharmaceuticals Inc, 2021

Retinal Vein Occlusion – Pipeline by Kiora Pharmaceuticals Inc, 2021

Retinal Vein Occlusion – Pipeline by Kodiak Sciences Inc, 2021

Retinal Vein Occlusion – Pipeline by Luye Pharma Group Ltd, 2021

Retinal Vein Occlusion – Pipeline by Novartis AG, 2021

Retinal Vein Occlusion – Pipeline by Novelty Nobility Inc, 2021

Retinal Vein Occlusion – Pipeline by Ocular Therapeutix Inc, 2021

Retinal Vein Occlusion – Pipeline by Outlook Therapeutics Inc, 2021

Retinal Vein Occlusion – Pipeline by Oxular Ltd, 2021

Retinal Vein Occlusion – Pipeline by Oxurion NV, 2021

Retinal Vein Occlusion – Pipeline by Ripple therapeutics Corp, 2021

Retinal Vein Occlusion – Pipeline by Samsung Bioepis Co Ltd, 2021

Retinal Vein Occlusion – Pipeline by SIFI SpA, 2021

Retinal Vein Occlusion – Pipeline by Uni-Bio Science Group Ltd, 2021

Retinal Vein Occlusion – Dormant Projects, 2021

Retinal Vein Occlusion – Dormant Projects, 2021 (Contd..1)

Retinal Vein Occlusion – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Retinal Vein Occlusion, 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.